Which is not used in the management of IPF?
**Core Concept**
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by fibrosis and scarring of lung tissue, leading to impaired gas exchange and respiratory failure. Management of IPF aims to slow disease progression, improve quality of life, and alleviate symptoms.
**Why the Correct Answer is Right**
The management of IPF typically involves pharmacological interventions to slow disease progression, such as antifibrotic agents. These medications target specific pathways involved in fibrosis, including the activation of fibroblasts and the deposition of extracellular matrix proteins. **Nintedanib** and **Pirfenidone** are two commonly used antifibrotic agents that have demonstrated efficacy in delaying disease progression in patients with IPF.
**Why Each Wrong Option is Incorrect**
* **Option A:** Nintedanib is used in the management of IPF, as it inhibits tyrosine kinases involved in fibrosis, making this option incorrect.
* **Option B:** Pirfenidone is also used in IPF management, as it modulates the activity of fibroblasts and reduces inflammation, making this option incorrect.
* **Option C:** Lung transplantation is a treatment option for patients with advanced IPF, but it is not a pharmacological agent used in the management of IPF, making this option correct.
**Clinical Pearl / High-Yield Fact**
Lung transplantation is a viable treatment option for patients with advanced IPF, but it carries significant risks and should be considered only for those with severe disease and limited life expectancy.
**Correct Answer:** C. Lung transplantation is a treatment option for patients with advanced IPF, but it is not a pharmacological agent used in the management of IPF.